proxyvotesnow.com

Home › Companies › Lifecore Biomedical, Inc. › 2025-2026

Lifecore Biomedical, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Lifecore Biomedical, Inc.’s Form 8-K, filed 2026-06-05 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 22Reported items
  • 128Asset managers
  • 1,877Fund votes
  • 2026-06-04Main meeting date

Proxy season: 2024-2025 2025-2026

Explore Lifecore Biomedical, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Lifecore Biomedical, Inc.

These tallies are Lifecore Biomedical, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Lifecore Biomedical, Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

Lifecore Biomedical, Inc. — official shareholder meeting results, meeting held 2026-06-04 (Form 8-K, filed 2026-06-05)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Katrina L. Houde 19,790,3593,336,694-- 3,35010,697,326 Majority: yes
Elect Director: Humberto C. Antunes 21,713,6611,408,873-- 7,86910,697,326 Majority: yes
Elect Director: Paul H. Johnson 21,920,2541,206,182-- 3,96710,697,326 Majority: yes
Elect Director: Paul Josephs 23,068,70757,729-- 3,96710,697,326 Majority: yes
Elect Director: Matthew E. Korenberg 21,432,5861,693,825-- 3,99210,697,326 Majority: yes
Elect Director: Nelson Obus 21,450,6471,675,206-- 4,55010,697,326 Majority: yes
Elect Director: Joshua E. Schechter 20,394,2782,731,575-- 4,55010,697,326 Majority: yes
As a result of the foregoing voting results, each of the foregoing directors was elected to the Board of Directors of the Company to serve for a term expiring at the 2027 Annual Meeting and until their successors are duly elected and qualif 33,760,87963,4453,405 ---- Majority: yes
Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: 22,938,684178,86812,851 --10,697,326 Passed
4.Stockholders approved the Lifecore Biomedical, Inc. 22,724,492392,82513,086 --10,697,326 Majority: yes

Source: Lifecore Biomedical, Inc., Form 8-K, filed with the SEC on 2026-06-05 — read the filing on EDGAR.

Lifecore Biomedical, Inc. — official shareholder meeting results, meeting held 2025-10-29 (Form 8-K, filed 2025-10-31)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Katrina L. Houde 22,373,2642,525,413-- 62,20110,786,809 Majority: yes
Elect Director: Humberto C. Antunes 24,631,549247,047-- 82,28210,786,809 Majority: yes
Elect Director: Paul H. Johnson 24,772,580122,686-- 65,61210,786,809 Majority: yes
Elect Director: Paul Josephs 24,847,35047,427-- 66,10110,786,809 Majority: yes
Elect Director: Matthew E. Korenberg 23,547,8871,347,390-- 65,60110,786,809 Majority: yes
Elect Director: Nelson Obus 24,351,643534,854-- 74,38110,786,809 Majority: yes
Elect Director: Joshua E. Schechter 22,169,3662,725,910-- 65,60210,786,809 Majority: yes
As a result of the foregoing voting results, each of the foregoing directors was appointed to the Board of Directors of the Company to serve for a term expiring at the 2026 Annual Meeting and until their successors are duly elected and qual 35,663,64315,32668,718 ---- Majority: yes
Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: 24,642,130238,35480,394 --10,786,809 Passed

Source: Lifecore Biomedical, Inc., Form 8-K, filed with the SEC on 2025-10-31 — read the filing on EDGAR.

How asset managers voted at the Lifecore Biomedical, Inc. 2025-2026 meetings

Each item below shows how the 128 asset managers that disclosed a Lifecore Biomedical, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Lifecore Biomedical, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve a non-binding advisory proposal on the executive compensation of the Company's named executive officers, as described in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

99.2% Passed · of votes cast

FOR 99.2%
FOR: 22,938,684AGAINST: 178,868

Lifecore Biomedical, Inc.’s own tally for this item (“Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows:”): 22,938,684 for, 178,868 against — passed, per its Form 8-K filed 2026-06-05 (Item 5.07). Of all 37,509,407 outstanding shares: 61% for, 0.5% against (62% of the company cast a for/against vote).

The 106 asset managers below cast 99.3% of the shares they voted on this item FOR (16,760,966 for, 108,836 against).

FOR 99.3%
FOR: 16,760,966 (99.4%)AGAINST: 108,836 (0.6%)
Largest asset managers voting on “To approve a non-binding advisory proposal on the executive compensation of the Company's named executive offi” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
WYNNEFIELD CAPITAL INC4,439,8400 00For
Legion Partners Asset Management, LLC4,403,7540 00For
325 CAPITAL LLC2,161,2120 00For
Vanguard1,623,0040 00For
BlackRock1,204,2670 00For
GEODE CAPITAL MANAGEMENT, LLC566,6050 00For
Fidelity446,7710 00For
State Street339,2060 00For
WITTENBERG INVESTMENT MANAGEMENT, INC.299,4150 00For
Charles Schwab159,7750 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.151,7000 00For
Northern Trust116,7000 00For
Equitable106,6110 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC103,5680 00For
Gabelli86,0000 00For
MELLON INVESTMENTS Corp083,168 00Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC61,8000 00For
BRIDGEWAY FUNDS INC56,9000 00For
Goldman Sachs47,9910 00For
Nuveen35,8500 00For
TIAA35,8500 00For
West Tower Group, LLC35,4240 00For
T. Rowe Price28,2130 00For
Corient Private Wealth LP27,7890 00For
STATE OF WISCONSIN INVESTMENT BOARD19,3660 00For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

2. To approve a non-binding advisory proposal on the executive compensation of the Company's named executive officers, as described in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

99.0% Passed · of votes cast

FOR 99.0%
FOR: 24,642,130AGAINST: 238,354

Lifecore Biomedical, Inc.’s own tally for this item (“Proposal 3: Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows:”): 24,642,130 for, 238,354 against — passed, per its Form 8-K filed 2025-10-31 (Item 5.07). Of all 37,509,407 outstanding shares: 66% for, 0.7% against (66% of the company cast a for/against vote).

The 87 asset managers below cast 98% of the shares they voted on this item FOR (11,407,299 for, 202,272 against).

FOR 98%
FOR: 11,407,299 (97.8%)AGAINST: 202,272 (1.7%)ABSTAIN: 56,435 (0.5%)
Largest asset managers voting on “To approve a non-binding advisory proposal on the executive compensation of the Company's named executive offi” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
WYNNEFIELD CAPITAL INC4,699,7790 00For
BlackRock1,394,2930 00For
325 CAPITAL LLC1,369,1540 00For
Vanguard1,286,5880 00For
GEODE CAPITAL MANAGEMENT, LLC623,9960 00For
Fidelity568,4890 00For
State Street460,6710 00For
Charles Schwab156,9420 00For
Northern Trust154,8940 00For
Equitable120,9880 00For
Gabelli86,5000 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC84,2390 00For
MELLON INVESTMENTS Corp076,308 00Against
Invesco070,348 00Against
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.00 50,3370Abstain
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Citadel34,6330 00For
T. Rowe Price30,2350 00For
Goldman Sachs29,7200 00For
WisdomTree024,621 00Against
John Hancock21,2110 00For
Nuveen20,5950 00For
TIAA20,5950 00For
Lincoln Financial19,3000 00For
Diversified Trust Co18,1460 00For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

3. TO APPROVE THE LIFECORE BIOMEDICAL, INC. 2026 STOCK INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 22,724,492AGAINST: 392,825

Lifecore Biomedical, Inc.’s own tally for this item (“4.Stockholders approved the Lifecore Biomedical, Inc.”): 22,724,492 for, 392,825 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 61% for, 1% against (62% of the company cast a for/against vote).

The 37 asset managers below cast 99% of the shares they voted on this item FOR (7,045,149 for, 84,554 against).

FOR 99%
FOR: 7,045,149 (98.8%)AGAINST: 84,554 (1.2%)
Largest asset managers voting on “TO APPROVE THE LIFECORE BIOMEDICAL, INC. 2026 STOCK INCENTIVE PLAN.” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Legion Partners Asset Management, LLC4,403,7540 00For
Vanguard1,367,0601 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable28,61178,000 00Against
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA35,8500 00For
Lincoln Financial19,3000 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya4,6630 00For
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli03,500 00Against
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century02,317 00Against
Venerable Variable Insurance Trust2,2860 00For
Calvert2,0870 00For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

Meeting held 2026-06-04.

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (2,725,949 for, 0 against).

FOR: 2,725,949 (100.0%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,367,0610 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable106,6110 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA35,8500 00For
Lincoln Financial19,3000 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya4,6630 00For
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert2,0870 00For
Principal1,8800 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

Meeting held 2025-10-29.

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (3,157,689 for, 0 against).

FOR: 3,157,689 (100.0%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,240,9390 00For
BlackRock795,1960 00For
Fidelity567,1330 00For
Equitable135,7790 00For
Charles Schwab87,6820 00For
BRIDGEWAY FUNDS INC56,9000 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco33,6820 00For
WisdomTree24,6210 00For
TIAA20,5950 00For
Lincoln Financial19,3000 00For
Northern Trust15,8760 00For
AIG/SunAmerica14,3720 00For
Global X13,7150 00For
Goldman Sachs12,2000 00For
John Hancock10,5820 00For
Pacific Life9,6770 00For
Bridge Builder Trust7,8690 00For
Voya7,6890 00For
Nationwide6,5570 00For
ProShares6,2140 00For
DWS4,2260 00For
Victory Capital3,6520 00For
Gabelli3,5000 00For
T. Rowe Price2,5950 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

6. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Humberto C. Antunes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 21,713,661AGAINST: 1,408,873

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Humberto C. Antunes”): 21,713,661 for, 1,408,873 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 58% for, 4% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 98% of the shares they voted on this item FOR (2,656,555 for, 50,094 against).

FOR 98%
FOR: 2,656,555 (98.1%)AGAINST: 50,094 (1.9%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,367,0574 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable99,1217,490 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA035,850 00Against
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya04,663 00Against
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert02,087 00Against
Principal1,8800 00For
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

7. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Joshua E. Schechter

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 20,394,278AGAINST: 2,731,575

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Joshua E. Schechter”): 20,394,278 for, 2,731,575 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 54.4% for, 7% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 77% of the shares they voted on this item FOR (2,092,193 for, 614,456 against).

FOR 77%AGAINST 23%
FOR: 2,092,193 (77.3%)AGAINST: 614,456 (22.7%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,362,8984,163 00For
BlackRock507,1810 00For
Fidelity0445,924 00Against
Equitable99,1217,490 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC056,900 00Against
TIAA035,850 00Against
Goldman Sachs19,0780 00For
Global X013,419 00Against
AIG/SunAmerica013,242 00Against
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares06,155 00Against
Voya04,663 00Against
DWS04,226 00Against
Victory Capital03,935 00Against
Gabelli3,5000 00For
John Hancock03,468 00Against
Meeder Funds02,873 00Against
SEI02,400 00Against
American Century02,317 00Against
Venerable Variable Insurance Trust02,286 00Against
Calvert02,087 00Against
Principal01,880 00Against
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

8. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Katrina L. Houde

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST 14%
FOR: 19,790,359AGAINST: 3,336,694

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Katrina L. Houde”): 19,790,359 for, 3,336,694 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 52.8% for, 9% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 76% of the shares they voted on this item FOR (2,049,501 for, 657,147 against).

FOR 76%AGAINST 24%
FOR: 2,049,501 (75.7%)AGAINST: 657,147 (24.3%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,362,8964,164 00For
BlackRock0507,181 00Against
Fidelity445,724200 00For
Equitable78,00028,611 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC056,900 00Against
TIAA35,8500 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica013,242 00Against
Pacific Life08,950 00Against
Bridge Builder Trust07,869 00Against
ProShares06,155 00Against
Voya04,663 00Against
DWS04,226 00Against
Victory Capital03,935 00Against
Gabelli3,5000 00For
John Hancock03,468 00Against
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century02,317 00Against
Venerable Variable Insurance Trust2,2860 00For
Calvert02,087 00Against
Principal01,880 00Against
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

9. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Matthew E. Korenberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 21,432,586AGAINST: 1,693,825

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Matthew E. Korenberg”): 21,432,586 for, 1,693,825 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 57% for, 5% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 99.3% of the shares they voted on this item FOR (2,688,131 for, 18,518 against).

FOR 99.3%
FOR: 2,688,131 (99.3%)AGAINST: 18,518 (0.7%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,365,7191,342 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable99,1217,490 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA35,8500 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya04,663 00Against
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert02,087 00Against
Principal1,8800 00For
State Street01,268 00Against

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

10. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Nelson Obus

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 21,450,647AGAINST: 1,675,206

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Nelson Obus”): 21,450,647 for, 1,675,206 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 57% for, 4% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 98% of the shares they voted on this item FOR (2,653,594 for, 53,055 against).

FOR 98%
FOR: 2,653,594 (98.0%)AGAINST: 53,055 (2.0%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,364,2382,823 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable99,1217,490 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA035,850 00Against
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya04,663 00Against
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert02,087 00Against
Principal1,8800 00For
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

11. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Paul H. Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 21,920,254AGAINST: 1,206,182

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Paul H. Johnson”): 21,920,254 for, 1,206,182 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 58% for, 3% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 99.5% of the shares they voted on this item FOR (2,694,492 for, 12,157 against).

FOR 99.5%
FOR: 2,694,492 (99.6%)AGAINST: 12,157 (0.4%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,367,0574 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable99,1217,490 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA35,8500 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya04,663 00Against
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert2,0870 00For
Principal1,8800 00For
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

12. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Paul Josephs

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 23,068,707AGAINST: 57,729

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Paul Josephs”): 23,068,707 for, 57,729 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 62% for, 0.2% against (62% of the company cast a for/against vote).

The 35 asset managers below cast 99.8% of the shares they voted on this item FOR (2,701,986 for, 4,663 against).

FOR 99.8%
FOR: 2,701,986 (99.8%)AGAINST: 4,663 (0.2%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,367,0610 00For
BlackRock507,1810 00For
Fidelity445,9240 00For
Equitable106,6110 00For
Charles Schwab79,8030 00For
BRIDGEWAY FUNDS INC56,9000 00For
TIAA35,8500 00For
Goldman Sachs19,0780 00For
Global X13,4190 00For
AIG/SunAmerica13,2420 00For
Pacific Life8,9500 00For
Bridge Builder Trust7,8690 00For
ProShares6,1550 00For
Voya04,663 00Against
DWS4,2260 00For
Victory Capital3,9350 00For
Gabelli3,5000 00For
John Hancock3,4680 00For
Meeder Funds2,8730 00For
SEI2,4000 00For
American Century2,3170 00For
Venerable Variable Insurance Trust2,2860 00For
Calvert2,0870 00For
Principal1,8800 00For
State Street1,2680 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

13. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Humberto C. Antunes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 24,631,549AGAINST: 247,047

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Humberto C. Antunes”): 24,631,549 for, 247,047 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 66% for, 0.7% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 99.0% of the shares they voted on this item FOR (3,022,477 for, 28,284 against).

FOR 99.0%
FOR: 3,022,477 (99.1%)AGAINST: 28,284 (0.9%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock795,1960 00For
Fidelity567,0390 00For
Equitable120,9880 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco33,6820 00For
WisdomTree24,6210 00For
TIAA020,595 00Against
Lincoln Financial19,3000 00For
Northern Trust15,8760 00For
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica11,2210 00For
John Hancock10,5820 00For
Bridge Builder Trust7,8690 00For
Voya07,689 00Against
Nationwide6,5570 00For
ProShares6,2140 00For
Victory Capital3,6520 00For
Pacific Life3,5740 00For
Gabelli3,5000 00For
T. Rowe Price2,5950 00For
SEI2,4000 00For
Brighthouse2,3460 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

14. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Joshua E. Schechter

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 22,169,366AGAINST: 2,725,910

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Joshua E. Schechter”): 22,169,366 for, 2,725,910 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 59% for, 7% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 66% of the shares they voted on this item FOR (2,006,476 for, 1,051,893 against).

FOR 66%AGAINST 34%
FOR: 2,006,476 (65.6%)AGAINST: 1,051,893 (34.4%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock0795,196 00Against
Fidelity567,0390 00For
Equitable78,50050,096 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC043,364 00Against
Invesco33,6820 00For
WisdomTree024,621 00Against
TIAA020,595 00Against
Lincoln Financial019,300 00Against
Northern Trust015,876 00Against
Global X013,715 00Against
Goldman Sachs12,2000 00For
AIG/SunAmerica011,221 00Against
John Hancock010,582 00Against
Bridge Builder Trust07,869 00Against
Voya07,689 00Against
Nationwide06,557 00Against
ProShares06,214 00Against
Victory Capital03,652 00Against
Pacific Life03,574 00Against
Gabelli3,5000 00For
T. Rowe Price02,595 00Against
SEI02,400 00Against
Brighthouse02,346 00Against

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

15. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Katrina L. Houde

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 22,373,264AGAINST: 2,525,413

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Katrina L. Houde”): 22,373,264 for, 2,525,413 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 60% for, 7% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 68% of the shares they voted on this item FOR (2,064,807 for, 985,954 against).

FOR 68%AGAINST 32%
FOR: 2,064,807 (67.7%)AGAINST: 985,954 (32.3%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock0795,196 00Against
Fidelity567,0390 00For
Equitable78,50042,488 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC043,364 00Against
Invesco33,6820 00For
WisdomTree024,621 00Against
TIAA20,5950 00For
Lincoln Financial19,3000 00For
Northern Trust015,876 00Against
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica011,221 00Against
John Hancock010,582 00Against
Bridge Builder Trust07,869 00Against
Voya07,689 00Against
Nationwide06,557 00Against
ProShares06,214 00Against
Victory Capital03,652 00Against
Pacific Life03,574 00Against
Gabelli3,5000 00For
T. Rowe Price02,595 00Against
SEI2,4000 00For
Brighthouse02,346 00Against

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

16. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Matthew E. Korenberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 23,547,887AGAINST: 1,347,390

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Matthew E. Korenberg”): 23,547,887 for, 1,347,390 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 63% for, 4% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 95% of the shares they voted on this item FOR (2,908,671 for, 142,090 against).

FOR 95%
FOR: 2,908,671 (95.3%)AGAINST: 142,090 (4.7%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock795,1960 00For
Fidelity567,0390 00For
Equitable120,9880 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco033,682 00Against
WisdomTree024,621 00Against
TIAA20,5950 00For
Lincoln Financial019,300 00Against
Northern Trust015,876 00Against
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica011,221 00Against
John Hancock010,582 00Against
Bridge Builder Trust7,8690 00For
Voya07,689 00Against
Nationwide6,5570 00For
ProShares06,214 00Against
Victory Capital03,652 00Against
Pacific Life3,5740 00For
Gabelli3,5000 00For
T. Rowe Price02,595 00Against
SEI2,4000 00For
Brighthouse02,346 00Against

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

17. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Nelson Obus

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 24,351,643AGAINST: 534,854

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Nelson Obus”): 24,351,643 for, 534,854 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 65% for, 1% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 99.0% of the shares they voted on this item FOR (3,022,358 for, 28,403 against).

FOR 99.0%
FOR: 3,022,358 (99.1%)AGAINST: 28,403 (0.9%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock795,1960 00For
Fidelity567,0390 00For
Equitable120,9880 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco33,6820 00For
WisdomTree24,6210 00For
TIAA020,595 00Against
Lincoln Financial19,3000 00For
Northern Trust15,8760 00For
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica11,2210 00For
John Hancock10,5820 00For
Bridge Builder Trust7,8690 00For
Voya07,689 00Against
Nationwide6,5570 00For
ProShares6,2140 00For
Victory Capital3,6520 00For
Pacific Life3,5740 00For
Gabelli3,5000 00For
T. Rowe Price2,5950 00For
SEI2,4000 00For
Brighthouse2,3460 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

18. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Paul H. Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 24,772,580AGAINST: 122,686

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Paul H. Johnson”): 24,772,580 for, 122,686 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 66% for, 0.4% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 99.7% of the shares they voted on this item FOR (3,050,680 for, 7,689 against).

FOR 99.7%
FOR: 3,050,680 (99.7%)AGAINST: 7,689 (0.3%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock795,1960 00For
Fidelity567,0390 00For
Equitable128,5960 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco33,6820 00For
WisdomTree24,6210 00For
TIAA20,5950 00For
Lincoln Financial19,3000 00For
Northern Trust15,8760 00For
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica11,2210 00For
John Hancock10,5820 00For
Bridge Builder Trust7,8690 00For
Voya07,689 00Against
Nationwide6,5570 00For
ProShares6,2140 00For
Victory Capital3,6520 00For
Pacific Life3,5740 00For
Gabelli3,5000 00For
T. Rowe Price2,5950 00For
SEI2,4000 00For
Brighthouse2,3460 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

19. To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at the next succeeding annual meeting of stockholders and until their successors are duly elected and qualified: Paul Josephs

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-10-29.

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 24,847,350AGAINST: 47,427

Lifecore Biomedical, Inc.’s own tally for this item (“Elect Director: Paul Josephs”): 24,847,350 for, 47,427 against, per its Form 8-K filed 2025-10-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,509,407 outstanding shares: 66% for, 0.2% against (66% of the company cast a for/against vote).

The 29 asset managers below cast 99.7% of the shares they voted on this item FOR (3,043,072 for, 7,689 against).

FOR 99.7%
FOR: 3,043,072 (99.7%)AGAINST: 7,689 (0.3%)
Largest asset managers voting on “To elect seven non-Series A Preferred Directors, as described in the Proxy Statement, for a term expiring at t” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,223,2760 00For
BlackRock795,1960 00For
Fidelity567,0390 00For
Equitable120,9880 00For
Charles Schwab87,6820 00For
QUANTITATIVE MASTER SERIES LLC43,3640 00For
Invesco33,6820 00For
WisdomTree24,6210 00For
TIAA20,5950 00For
Lincoln Financial19,3000 00For
Northern Trust15,8760 00For
Global X13,7150 00For
Goldman Sachs12,2000 00For
AIG/SunAmerica11,2210 00For
John Hancock10,5820 00For
Bridge Builder Trust7,8690 00For
Voya07,689 00Against
Nationwide6,5570 00For
ProShares6,2140 00For
Victory Capital3,6520 00For
Pacific Life3,5740 00For
Gabelli3,5000 00For
T. Rowe Price2,5950 00For
SEI2,4000 00For
Brighthouse2,3460 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

20. PROPOSAL NO LONGER VALID

DIRECTOR ELECTIONS

Meeting held 2025-10-29.

100% fund support · no official result

9%ABSTAIN 91%

The 8 asset managers below cast 100% of the shares they voted on this item FOR (82,716 for, 0 against).

FOR: 82,716 (8.8%)ABSTAIN: 857,011 (91.2%)
Largest asset managers voting on “PROPOSAL NO LONGER VALID” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock00 795,1960Abstain
Equitable78,5000 00For
QUANTITATIVE MASTER SERIES LLC00 43,3640Abstain
John Hancock00 10,5820Abstain
Bridge Builder Trust00 7,8690Abstain
Gabelli3,5000 00For
RBB FUND, INC.5970 00For
Advisors' Inner Circle Fund III1190 00For

21. Elect Christopher S. Kiper

DIRECTOR ELECTIONS

Meeting held 2025-10-29.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (103,797 for, 0 against).

FOR: 103,797 (100.0%)
Largest asset managers voting on “Elect Christopher S. Kiper” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Charles Schwab87,6820 00For
Global X13,7150 00For
SEI2,4000 00For

22. Elect Jason M. Aryeh

DIRECTOR ELECTIONS

Meeting held 2025-10-29.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (103,797 for, 0 against).

FOR: 103,797 (100.0%)
Largest asset managers voting on “Elect Jason M. Aryeh” at Lifecore Biomedical, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Charles Schwab87,6820 00For
Global X13,7150 00For
SEI2,4000 00For

Largest Lifecore Biomedical, Inc. shareholders voting in 2025-2026

Ranked by the number of Lifecore Biomedical, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 37,509,407 shares outstanding at the time of that meeting.

Top Lifecore Biomedical, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1WYNNEFIELD CAPITAL INC 11.84%
2Legion Partners Asset Management, LLC 11.74%
3325 CAPITAL LLC 5.76%
4Vanguard 4.33%
5BlackRock 3.21%
6GEODE CAPITAL MANAGEMENT, LLC 1.51%
7Fidelity 1.19%
8State Street 0.90%
9WITTENBERG INVESTMENT MANAGEMENT, INC. 0.80%
10Charles Schwab 0.43%

Reported Lifecore Biomedical, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Lifecore Biomedical, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Christopher S. Kiper 18.38% DEF14A
Legion Partners, LLC 17.91% 13D
Nelson Obus 14.54% DEF14A
Wynnefield Capital, Inc. 14.54% DEF14A
Greenhaven Road Investment Management, LP 9.64% DEF14A
22NW, LP 8.49% DEF14A
Capital 8.36% DEF14A
22NW Fund, LP 7.23% 13D
LW Capital Management 5.07% DEF14A
BlackRock 5.00% 13F

Percentages above are of 37,509,407 shares outstanding, as reported by Lifecore Biomedical, Inc. on its Form 10-Q dated 2026-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lifecore Biomedical, Inc.’s 10-Q dated 2026-04-29. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Lifecore Biomedical, Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held 2025-10-29 and 2026-06-04), 128 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,877 separate fund positions. Their filings are grouped here into 22 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2026-06-04 — To approve a non-binding advisory proposal on the executive compensation of the Company's named… — the proposal passed with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Lifecore Biomedical, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-05.

Lifecore Biomedical, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).